The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.

An organic molecule is disclosed having: a first chemical unit comprising or consisting of a structure according to formula I ##STR00001##
and two second chemical moieties, each at each occurrence independently from another comprising or consisting of a structure of formula II, ##STR00002##
wherein the first chemical moiety is linked to each of the two second chemical moieties via a single bond.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

##STR00001##

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

##STR00001##

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Disclosed are an organic compound based on triazine and benzoxazole and an application thereof in an OLED device. The compound of the present application has a relatively high glass transition temperature and molecular thermal stability, is low in absorption and high in refractive index in the field of visible light, and is capable of effectively improving the light extraction efficiency of an OLED device when applied to a capping layer of the OLED device; with a deep HOMO energy level and high electronic mobility, the compound of the present application can be used as the hole blocking layer or the electron transport layer material, so that the recombination degree of the hole and the electron in the light-emitting layer can be improved, and thus the light-emitting efficiency of the OLED device can be enhanced and the service life of the OLED device can be prolonged.

Disclosed are an organic compound based on triazine and benzoxazole and an application thereof in an OLED device. The compound of the present application has a relatively high glass transition temperature and molecular thermal stability, is low in absorption and high in refractive index in the field of visible light, and is capable of effectively improving the light extraction efficiency of an OLED device when applied to a capping layer of the OLED device; with a deep HOMO energy level and high electronic mobility, the compound of the present application can be used as the hole blocking layer or the electron transport layer material, so that the recombination degree of the hole and the electron in the light-emitting layer can be improved, and thus the light-emitting efficiency of the OLED device can be enhanced and the service life of the OLED device can be prolonged.

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

The present disclosure relates to novel macrocyclic compounds and libraries thereof containing heteroaryl moieties that are useful as research tools for drug discovery efforts. The present disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.